Immunovia AB (OSTO:IMMNOV)
kr 0.618 -0.01 (-1.59%) Market Cap: 104.88 Mil Enterprise Value: 76.83 Mil PE Ratio: 0 PB Ratio: 2.91 GF Score: 44/100

Q2 2019 Immunovia AB (publ) Earnings Call Transcript

Aug 23, 2019 / 02:00PM GMT
Release Date Price: kr70.54 (-3.65%)
Operator

Ladies and gentlemen, welcome to the Immunovia Interim Report January to June 2019. Today, I'm pleased to present Mats Grahn, CEO. (Operator Instructions)

Mats, please begin.

Mats Grahn;publ;CEO
Immunovia AB

()-

Welcome to the call, everyone. I'll talk about the first half of 2019 and the quarter 2, specifically. This is the peer data that, of course, was characterized by the major milestone that we reached in the second quarter when we completed the optimization study with excellent results, and we'll spend quite a long time on this one today, going through the very, very good results and what they mean.

But before that, I'd just like to comment shortly on the financials that we have released also today. And there, you can see that the cash position is very well. We are well financed. We have SEK 327 million at the end of the period. And that will take us approximately 2 years from now on moving forward with the current business plan.

Burn rate, January to June, was approximately SEK 60 million, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot